{"product_id":"biotechnology-valuation-karl-keegan-9780470511787","title":"Biotechnology Valuation: An Introductory Guide","description":"\u003cul\u003e \u003cli\u003eThe first book to provide a simple and practical means of valuing biotech companies\u003c\/li\u003e \u003cli\u003eThe book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips\u003c\/li\u003e \u003cli\u003eIt examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US\u003c\/li\u003e \u003cli\u003eLooks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them\u003c\/li\u003e \u003c\/ul\u003e \u003cb\u003ePraise for \u003ci\u003eBiotechnology Valuation\u003c\/i\u003e\u003c\/b\u003e \u003cp\u003e\"Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start.\"\u003cbr\u003e --\u003cb\u003eChris Blackwell\u003c\/b\u003e, Chief Executive, Vectura Group plc\u003c\/p\u003e \u003cp\u003e\"A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians.\"\u003cbr\u003e --\u003cb\u003eSteve Winokur\u003c\/b\u003e, Managing Director, CanaccordAdams\u003c\/p\u003e \u003cp\u003e\"A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value.\"\u003cbr\u003e --\u003cb\u003eDr L.M. Allan\u003c\/b\u003e, Director, Bioscience Enterprise Programme, University of Cambridge\u003c\/p\u003e \u003cp\u003e\"A fabulous approach to a difficult topic.\"\u003cbr\u003e --\u003cb\u003eDeirdre Y. Gillespie\u003c\/b\u003e, MD, President \u0026amp; CEO, La Jolla Pharmaceutical Company\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Karl Keegan\u003cbr\u003e\u003cb\u003eISBN-10:\u003c\/b\u003e 0470511788\u003cbr\u003e\u003cb\u003eISBN-13:\u003c\/b\u003e 9780470511787\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Wiley\u003cbr\u003e\u003cb\u003eLanguage:\u003c\/b\u003e English\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 01\/14\/2009\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 224\u003cbr\u003e\u003cb\u003eFormat:\u003c\/b\u003e Hardcover\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 1.25lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 9.60h x 6.50w x 1.00d","brand":"Karl Keegan","offers":[{"title":"Hardcover","offer_id":43919857516799,"sku":"9780470511787","price":108.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/2982\/9887\/products\/img_e1980d14-9448-4fbe-8963-a20b033ed423.jpg?v=1680812289","url":"https:\/\/www.whiterainbookhouse.com\/products\/biotechnology-valuation-karl-keegan-9780470511787","provider":"WR Book House","version":"1.0","type":"link"}